ZURICH (Reuters) – Lonza and Moderna are deepening their collaboration for COVID-19 vaccine production, with the Swiss contract drugmaker building a drug substance production line at a Dutch site to add capacity of up to 300 million doses annually.
The new production line is expected to be operational by the end of 2021.
(Reporting by John Miller; Editing by Riham Alkousaa)
